NYBA
New York Biotechnology Association
 
 
More...
NYBA: Member News
Archived News | Press Release | NYBA News
 
 
 
Applied DNA Sciences, Inc.
Headline: Applied DNA Sciences Validates Use Of SigNature DNA In Laminates Used In Government
Identification Cards And Other Secure Documents
Date: 09-Jun-2009
Applied DNA Sciences Validates Use of SigNature DNA in Laminates Used in Government Identification Cards and Other Secure Documents STONY BROOK, N.Y., June 9, 2009 /Market Wire/ -- Applied DNA Sciences, Inc. (OTC Bulletin Board: APDN), a provider of DNA-based security solutions, announced today that in collaboration with a world leader in security laminated materials, it has val... .
Details »
 
 
Enzo Biochem Inc.
Headline: Data From Enzo Therapeutics' Phase II Study Of Crohn's Disease Presented At
Prestigious Gastroenterology Conference
Date: 02-Jun-2009
Data from Enzo Therapeutics' Phase II Study of Crohn's Disease Presented at Prestigious Gastroenterology Conference Study Meets Primary and Secondary Endpoints NEW YORK--(BUSINESS WIRE)--Jun 2, 2009 - Enzo Biochem, Inc. (NYSE: ENZ), a biotechnology company specializing in gene identification and genetic and immune regulation technologies for diagnostic and... .
Details »
 
 
ZIOPHARM Oncology, Inc.
Headline: ZIOPHARM Presents Positive Data From Phase I Study Of Palifosfamide In Combination
with Doxorubicin
Date: 01-Jun-2009
ZIOPHARM Presents Positive Data from Phase I Study of Palifosfamide in Combination with Doxorubicin at ASCO -- Continued Safety and Activity Strongly Support OngoingPhase II Randomized Trial -- ORLANDO, Fla., May 31, 2009 (BUSINESS WIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today that it presented final data from a Phase I study of palifosfam... .
Details »
 
 
Bristol-Myers Squibb Company
Headline: Results From Three Phase 2 Studies Reported A Two-Year Survival Rate Ranging From 30
to 42 Percent In Metastatic Melanoma Patients Treated With Ipilim
Date: 01-Jun-2009
Results from Three Phase 2 Studies Reported a Two-Year Survival Rate Ranging from 30 to 42 Percent in Metastatic Melanoma Patients Treated with Ipilimumab (10 mg/kg) Results from First Biomarker Analysis of Phase 2 Ipilimumab Studies also Presented PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Medarex, Inc. (NASDAQ: MEDX)... .
Details »
 
 
ZIOPHARM Oncology, Inc.
Headline: ZIOPHARM Presents Positive Darinaparsin Clinical Data At ASCO's Prestigious Clinical
Science Symposium
Date: 01-Jun-2009
ZIOPHARM Presents Positive Darinaparsin Clinical Data at ASCO's Prestigious Clinical Science Symposium Phase II Results Possible Basis for FDA DialogueRegarding Registration Trial ORLANDO, Fla., Jun 01, 2009 (BUSINESS WIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today that it presented positive data from both Phase II intravenous (IV) and Phas... .
Details »
 
 
Pfizer Inc.
Headline: Pfizer Data Identify Certain Lung Cancer Patients Who May Benefit From Treatment With
Figitumumab
Date: 30-May-2009
Pfizer Data Identify Certain Lung Cancer Patients Who May Benefit from Treatment with Figitumumab Research explores biomarkers as potential predictors of sensitivity to treatment ORLANDO, Fla.--(BUSINESS WIRE)--Pfizer announced today results from studies evaluating the company’s investigational anti-insulin growth factor- type 1 receptor (IGF-1R) an... .
Details »
 
 
OSI Pharmaceuticals Inc.
Headline: Data From The Phase III ATLAS Study Show Tarceva In Combination With Avastin As
First-Line Maintenance Therapy Improved Progression-Free Survival In A
Date: 30-May-2009
Data from the Phase III ATLAS Study Show Tarceva in Combination with Avastin as First-Line Maintenance Therapy Improved Progression-Free Survival in Advanced Lung Cancer -- Study is Second Positive Phase III Trial of Tarceva as First-Line Maintenance Therapy -- ORLANDO, Fla., May 30, 2009 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced... .
Details »
 
 
Genentech Inc.
Headline: Phase III Study Showed Patients Lived Longer Without Advanced Lung Cancer Progressing
When Tarceva Was Added To Avastin As First-Line Maintenance Ther
Date: 30-May-2009
Phase III Study Showed Patients Lived Longer Without Advanced Lung Cancer Progressing When Tarceva Was Added to Avastin as First-Line Maintenance Therapy Orlando, Fla. --  May 30, 2009 --  Genentech, Inc. today announced that a Phase III study (ATLAS) showed patients with advanced non-small cell lung cancer (NSCLC) who received Tarceva® (erlotinib) in combination wi... .
Details »
 
 
Genentech Inc.
Headline: Genentech Announces Full Results From First Phase III Study Of Avastin In Early-Stage
Colon Cancer
Date: 30-May-2009
Genentech Announces Full Results from First Phase III Study of Avastin in Early-Stage Colon Cancer -- Study Does not Meet Endpoint; However, Results Suggest Future Trials May Hold Promise for Avastin as Adjuvant Colon Cancer Treatment -- Orlanddo, Fla. --  May 30, 2009 --  Genentech, Inc. today announced results from a Phase III study of Avastin® (bev... .
Details »
 
 
Pfizer Inc.
Headline: Pfizer Presents Data With Novel Investigational Agents In Select Patient Groups With
Non-Small Cell Lung Cancer
Date: 30-May-2009
Pfizer Presents Data With Novel Investigational Agents In Select Patient Groups With Non-Small Cell Lung Cancer Novel c-Met/ALK Inhibitor is the First Agent in Clinical Development to Selectively Target Sub-group of NSCLC Patients ORLANDO, Fla.--(BUSINESS WIRE)--Pfizer announced today results from four studies highlighting clinical data with targeted trea... .
Details »
 
   
  © 2008 New York Biotechnology Association HOME | ABOUT NYBA | CONTACT US | SITE MAP Website by Axxiem